| DESCRIPTION | - "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", Monoclonal Antibodies For Cancer Detection And Therapy, Academic Press, (19850000), pages 303 - 16 | - |
| DESCRIPTION | - "Antibodies For Drug Delivery", HELLSTROM et al., Controlled Drug Delivery, Marcel Dekker, Inc., (19870000), pages 623 - 53 | - |
| DESCRIPTION | - "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", THORPE, Monoclonal Antibodies '84: Biological And Clinical Applications, (19850000), pages 475 - 506 | - |
| DESCRIPTION | - BIRD et al., Science, (19880000), vol. 242, pages 423 - 426 | - |
| DESCRIPTION | - FISCHER, R. et al., Biol. Chem., (19990000), vol. 380, pages 825 - 839 | - |
| DESCRIPTION | - GLENN E. MORRIS, Epitope Mapping Protocols (Methods in Molecular Biology, ISBN 089603-375-9 | - |
| DESCRIPTION | - HOLLIGER, P. et al., Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, pages 6444 - 6448 | - |
| DESCRIPTION | - HUSTON et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, pages 5879 - 5883 | - |
| DESCRIPTION | - JONES, P. et al., Nature, (19860000), vol. 321, pages 522 - 525 | - |
| DESCRIPTION | - KRAUS et al., "Recombinant antibodies for cancer therapy", Methods in Molecular Biology series, ISBN 0-89603-918-8 | - |
| DESCRIPTION | - "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", AMON et al., Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., (19850000), pages 243 - 56 | - |
| DESCRIPTION | - NEDDLEMANWUNSCH, J. Mol. Biol., (19700000), vol. 48, page 443 | - |
| DESCRIPTION | - OLWYN M. R. WESTWOODFRANK C. HAY, "Epitope Mapping: A Practical Approach", Practical Approach Series, vol. 248 | - |
| DESCRIPTION | - PEARSONLIPMAN, Proc. Natl Acad. Sci. USA, (19880000), vol. 85, page 2444 | - |
| DESCRIPTION | - "Poljak, R.", Structure, (19940000), vol. 2, pages 1121 - 1123 | - |
| DESCRIPTION | - POLLOCK et al., J. Immunol. Meth., (19990000), vol. 231, pages 147 - 157 | - |
| DESCRIPTION | - QUEEN, C. et al., Proc. Natl. Acad. Sci. U. S. A., (19890000), vol. 86, pages 10029 - 10033 | - |
| DESCRIPTION | - RIECHMANN, L. et al., Nature, (19980000), vol. 332, pages 323 - 327 | - |
| DESCRIPTION | - ROSSI et al., Am. J. Clin. Pathol., (20050000), vol. 124, page 295 | - |
| DESCRIPTION | - SCATCHARD et al., Ann N.Y. Acad. ScL, (19490000), vol. 51, page 660 | - |
| DESCRIPTION | - SMITHWATERMAN, Ads App. Math., (19810000), vol. 2, page 482 | - |
| DESCRIPTION | - SPIEKER-POLET et al., Proc. Natl. Acad. Sci. U.S.A., (19950000), vol. 92, page 9348 | - |
| DESCRIPTION | - VERMA, R. et al., J. Immunol. Meth., (19980000), vol. 216, pages 165 - 181 | - |
| DESCRIPTION | - WARD et al., Nature, (19890000), vol. 341, pages 544 - 546 | - |
| DESCRIPTION | - ZITVOGEL L. et al., Cell, (20100000), vol. 140, pages 798 - 804 | - |
| DESCRIPTION | - THORPE et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev., (19820000), vol. 62, doi:10.1111/j.1600-065X.1982.tb00392.x, pages 119 - 58, XP001179872 | |
| OPPOSITION | - Anonymous, "P56856 · CLD18_HUMAN", UNIPROTKB, (20000530), Database accession no. 3P56856, XP093232994 | - |
| OPPOSITION | - Anonymous, "Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer", ClinicalTrials.gov; NCT00909025, (20170630), ClinicalTrials.gov; NCT00909025, URL: https://clinicaltrials.gov/study/NCT00909025?term=NCT00909025&rank=1&a=11, XP093233001 | - |
| OPPOSITION | - Anonymous Xiao Jun, Qiu Feng, Xiong Jian Ping, Zhang Ling, Yu Feng, Feng Miao, Zhan Zheng Yu, "A Phase II Trial of Epirubicin, Oxaliplatin, and Capecitabine (EOX) as First-Line Chemotherapy in Advanced Gastric Cancer: A Chinese Single-Center Experience | Chemotherapy | Karger Publishers", Karger - CHE, (20100101), Database accession no. 56/3/171/66736, XP093234745 | - |
| OPPOSITION | - Butt Waseem, Saadati Hamid, Saif Muhammad Wasif, "Oxaliplatin-induced Pancreatitis: A Case Series", ANTICANCER RESEARCH, (20101115), vol. 30, pages 5113 - 5116, XP093224802 | - |
| OPPOSITION | - "Carmustine", Wikipedia, (20230129), Wikipedia, URL: https://en.wikipedia.org/wiki/Carmustine, XP093224792 | - |
| OPPOSITION | - D10 - Submission filed during examination proceedings on February 17, 2022 of EP 20194625 | - |
| OPPOSITION | - D11 - Communication issued by the examining division dated May 11, 2022 The examination carried out on EP 20194625 | - |
| OPPOSITION | - D12 - Experimental Data - Chemotherapy treatment of NUGC-4 cells, Patu 8988s cells and BxPC3 cells | - |
| OPPOSITION | - D13 - Materials and methods Treatment of tumor cell lines with stress-inducing agents - for D12 | - |
| OPPOSITION | - D23 - Opponent’s Experimental Report - Cldnl8.2 expression over cell cultivation period without chemotherapeutic agents | - |
| OPPOSITION | - D37 - Information from ClinicalTrials.gov concerning the publication date of D36, specificallv the date "First Posted" | - |
| OPPOSITION | - D39 - Opposition arguments of Dörries-dfmp | - |
| OPPOSITION | - D40 - Appeal arguments of Dörries-dfmp | - |
| OPPOSITION | - D6 - EP 17171169 A - Interlocutory decision in opposition proceedings (Art. 101(3)(a) and 106(2) EPC) | - |
| OPPOSITION | - Debraud F., Munzone E., Nolè F., De Pas T., Biffi R., Brienza S., Aapro M. S., "Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil ", PubMed, (19980601), Database accession no. 9626798 , URL: NCBI, XP093234721 | - |
| OPPOSITION | - Eichhorst S T, Müerköster S., Weigand M.A., Krammer P.H. , "The Chemotherapeutic Drug 5-Fluorouracil Induces Apoptosis in Mouse Thymocytes in Vivo via Activation of the CD95(APO-1/Fas) System", Cancer Research, (20010101), vol. 61, pages 243 - 248, XP093091618 | - |
| OPPOSITION | - "Etoposide", Wikipedia, (20230128), Wikipedia, XP093224796 | - |
| OPPOSITION | - Felice Pasini, Anna Paola Fraccon, Giovanni De Manzoni, "The Role of Chemotherapy in Metastatic Gastric Cancer", Anticancer Research, (20111001), vol. 31, no. 10, pages 3543 - 3554, XP055819153 | - |
| OPPOSITION | - Fresenius Kabi, " LEUCOVORIN CALCIUM - leucovorin calcium injection - package insert", (20181101), pages 1 - 11, XP093229251 | - |
| OPPOSITION | - "Gastrointestinale Tumoren: Irinotecan erhöht die Chance, länger und besser zu überleben - Ergebnisse aus aktuellen klinischen Prüfungen", Clinical Investigators Update Meeting on Gastro-Intestinal Cancer - Beilage zu ONKOLOGIE, Band 25, Heft 3, Juni 2002, (20020420), vol. 25, pages 1 - 4, XP093230680 | - |
| OPPOSITION | - Jacobs C, Lyman G, Velez-García E, Sridhar K S, Knight W, Hochster H, Goodnough L T, Mortimer J E, Einhorn L H, Schacter L, "A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck", PubMed, (19920201), Database accession no. 1732427 , URL: NCBI, XP093234727 | - |
| OPPOSITION | - Michael Andreeff, Dietmar P. Berger, Benjamín Koziner, Monika Engelhardt, Hans A. Messner, Hartmut Henß, N. Thatcher, and Roland Mertelsmann, "Part 4 - Supportive Care - 4.7 - Bisphosphonates", Michael Andreeff, Dietmar P. Berger, Benjamín Koziner, Monika Engelhardt, Hans A. Messner, Hartmut Henß, N. Thatcher, and Roland Mertelsmann, Berger, Dietmar Paul, Andreeff, Michael, Concise manual of hematology and oncology : with 474 tables, DE, Berlin ; Heidelberg [u.a.] : Springer, (20080609), pages 528 - 780, ISBN 978-3-540-73276-1, XP009558580 | - |
| OPPOSITION | - Sulkes A, Smyth J, Sessa C, Dirix L Y, Vermorken J B, Kaye S, Wanders J, Franklin H, Lebail N, Verweij J, "Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial", Br Journal Cancer, (19940101), vol. 70, pages 380 - 383, XP093091440 | - |
| OPPOSITION | - Thierry André, Boni Corrado, Mounedji-Boudiaf Lamia, Navarro Matilde, Tabernero Josep, Hickish Tamas, Topham Clare, Zaninelli Marta, Clingan Philip, Bridgewater John, Tabah-Fisch Isabelle, De Gramont Aimery, "Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer", PubMed, (20040603), Database accession no. 15175436 , URL: NCBI, XP093234711 | - |
| OPPOSITION | - Van Cutsem E, Blijham G H, "Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group", PubMed, (19990226), Database accession no. 10213010, URL: NCBI, XP093234706 | - |
| OPPOSITION | - VELDERS M P, ET AL., "THE IMPACT OF ANTIGEN DENSITY AND ANTIBODY AFFINITY ON ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY: RELEVANCE FOR IMMUNOTHERAPY OF CARCINOMAS", British Journal of Cancer, GB, (19980801), vol. 78, no. 04, ISSN 0007-0920, pages 478 - 483, XP009027871 | - |
| OPPOSITION | - Hirotake Tokuyama; Tomomi Hagi; Stephen R. Mattarollo; Jacqueline Morley; Qiao Wang; Hang Fai‐So; Fuminori Moriyasu; Mie Nieda; Andrew J. Nicol, "Vγ9Vδ2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs—Rituximab and trastuzumab", International Journal of Cancer, US , (20080228), vol. 122, no. 11, doi:10.1002/ijc.23365, ISSN 0020-7136, pages 2526 - 2534, XP071285149 | |
| OPPOSITION | - Muñoz‐sánchez Jorge, Chánez‐cárdenas María E., "The use of cobalt chloride as a chemical hypoxia model", Journal of Applied Toxicology, GB , (20190401), vol. 39, no. 4, doi:10.1002/jat.3749, ISSN 0260-437X, pages 556 - 570, XP093091472 | |
| OPPOSITION | - Beverly A. Teicher, "Tumor Models in Cancer Research Second Edition /Passage/", Tumor Models in Cancer Research Second Edition, Springer Science+Business Media, LLC , (20110101), pages 106 - 598, doi:10.1007/978-1-60761-968-0, XP055819148 | |
| OPPOSITION | - Sahin U., Türeci Ö., Manikhas G., Lordick F., Rusyn A., Vynnychenko I., Dudov A., Bazin I., Bondarenko I., Melichar B., Dhaene K., Wiechen K., Huber C., Maurus D., Arozullah A., Park J.W., Schuler M., Al-Batran S.-E., "FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma", Annals of Oncology, (20210501), vol. 32, no. 5, doi:10.1016/j.annonc.2021.02.005, ISSN 0923-7534, pages 609 - 619, XP093116419 | |
| OPPOSITION | - de Gramont, A. Vignoud, J. Tournigand, C. Louvet, C. Andre, T. Varette, C. Raymond, E. Moreau, S. Le Bail, N. Krulik, M., "Oxaliplatin with High-dose Leucovorin and 5-Fluorouracil 48-hour Continuous Infusion in Pretreated Metastatic Colorectal Cancer", European Journal of Cancer, Elsevier, 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, (19970201), vol. 33, no. 2, doi:10.1016/S0959-8049(96)00370-X, ISSN 0959-8049, pages 214 - 219, XP004282501 | |
| OPPOSITION | - Schønnemann K R, Jensen H A, Yilmaz M, Jensen B V, Larsen O, Pfeiffer P, "Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer", British Journal of Cancer, GB, (20080901), vol. 99, no. 6, doi:10.1038/sj.bjc.6604569, ISSN 0007-0920, pages 858 - 861, XP093230685 | |
| OPPOSITION | - Shaulian Eitan; Karin Michael, "AP-1 in cell proliferation and survival", Oncogene, GB, (20010430), vol. 20, no. 19, doi:10.1038/sj.onc.1204383, ISSN 0950-9232, pages 2390 - 2400, XP037732227 | |
| OPPOSITION | - Roti Roti Joseph L, "Cellular responses to hyperthermia (40-46 degrees C): cell killing and molecular events", INTERNATIONAL JOURNAL OF HYPERTHERMIA, GB , (20080201), vol. 24, no. 1, doi:10.1080/02656730701769841, ISSN 0265-6736, pages 3 - 15, XP009167442 | |
| OPPOSITION | - Özlem Türeci, Mitnacht-Kraus Rita, Wöll Stefan, Yamada Tomohiro, Sahin Ugur, "Characterization of zolbetuximab in pancreatic cancer models", Oncoimmunolgy, US , (20190102), vol. 8, no. 1, doi:10.1080/2162402X.2018.1523096, ISSN 2162-4011, page e1523096, XP055678806 | |
| OPPOSITION | - DUCREUX M ET AL, "Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients.", Annals of Oncology, (20040301), vol. 15, no. 3, doi:10.1093/annonc/mdh098, pages 467 - 473, XP002420489 | |
| OPPOSITION | - EICHHORST SOEREN T ET AL, "A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs.", MOLECULAR AND CELLULAR BIOLOGY, US , (20001001), vol. 20, no. 20, doi:10.1128/MCB.20.20.7826-7837.2000, ISSN 0270-7306, pages 7826 - 7837, XP002194897 | |
| OPPOSITION | - Allum W. H., Blazeby J. M., Griffin S. M., Cunningham D., Jankowski J. A., Wong R., "Guidelines for the management of oesophageal and gastric cancer", Gut microbiota, British medical association, GB, (20111101), vol. 60, no. 11, doi:10.1136/gut.2010.228254, ISSN 0017-5749, pages 1449 - 1472, XP093091551 | |
| OPPOSITION | - Yano Koichi, Imaeda Takashi, Niimi Tomoaki, "Transcriptional activation of the human claudin-18 gene promoter through two AP-1 motifs in PMA-stimulated MKN45 gastric cancer cells", American Journal of Physiology - Gastrointestinal and Liver Physiology, US , (20071114), vol. 294, no. 1, doi:10.1152/ajpgi.00328.2007, ISSN 0193-1857, pages G336 - G343, XP093091614 | |
| OPPOSITION | - Niwa R; Sakurada M; Kobayashi Y; Uehara A; Matsushima K; Ueda R; Nakamura K; Shitara K, "Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density", Clinical Cancer Research, US, (20050315), vol. 11, no. 6, doi:10.1158/1078-0432.CCR-04-2263, ISSN 1078-0432, pages 2327 - 2336, XP009144270 | |
| OPPOSITION | - Ugur Sahin, Michael Koslowski, Karl Dhaene, Dirk Usener, Gunda Brandenburg, Gerhard Seitz, Christoph Huber , Özlem Türeci, "Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development.", Clinical Cancer Research, US, (20081201), vol. 14, no. 23, doi:10.1158/1078-0432.CCR-08-1547, ISSN 1078-0432, pages 7624 - 7634, XP002588324 | |
| OPPOSITION | - Omura Kenji, "Advances in Chemotherapy against Advanced or Metastatic Colorectal Cancer", DIGESTION, S. Karger AG., CH , (20080101), vol. 77, no. Suppl. 1, doi:10.1159/000111483, ISSN 0012-2823, pages 13 - 22, XP093229256 | |
| OPPOSITION | - Tetzlaff Eric, Ajani Jaffer, Cheng Jonathan, "Review of docetaxel in the treatment of gastric cancer", Therapeutics and Clinical Risk Management, (20081001), vol. 4, no. 5, doi:10.2147/TCRM.S3226, pages 999 - 1007, XP055819157 | |
| OPPOSITION | - Kontermann R E, "Strategies to extend plasma half-lives of recombinant antibodies", BIODRUGS, NZ , (20090401), vol. 23, no. 2, doi:10.2165/00063030-200923020-00003, ISSN 1173-8804, pages 93 - 109, XP008124089 | |
| OPPOSITION | - Sastre Javier, García-Saenz Jose Angel, Díaz-Rubio Eduardo, "Chemotherapy for gastric cancer", World Journal of Gastroenterology, CN , (20060101), vol. 12, no. 2, doi:10.3748/wjg.v12.i2.204, ISSN 1007-9327, pages 204 - 213, XP093091466 | |
| OPPOSITION | - Bagnyukova Tetyana V., Serebriiskii Ilya G., Zhou Yan, Hopper-Borge Elizabeth A., Golemis Erica A., Astsaturov Igor, "Chemotherapy and signaling : How can targeted therapies supercharge cytotoxic agents?", Cancer biology & therapy, US , (20101101), vol. 10, no. 9, doi:10.4161/cbt.10.9.13738, ISSN 1538-4047, pages 839 - 853, XP093091620 | |
| SEARCH | - Aristides Polyzos ET AL, "Subsets of Patients with Advanced Gastric Cancer Responding to Second-line Chemotherapy with Docetaxel - Cisplatin", Anticancer Research, Greece, (20060901), pages 3749 - 3754, URL: http://ar.iiarjournals.org/content/26/5B/3749.full.pdf#page=1&view=FitH, (20200114), XP055657695 [T] * the whole document * | - |
| SEARCH | - Ganymed Pharmaceuticals Gmbh, "Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal CancerNCT00909025", ClinicalTrials.gov, (20090327), URL: http://citenpl.internal.epo.org/wf/web/citenpl/citenpl.html, (20181115), XP055524253 [A] 1-14 * the whole document * | - |
| SEARCH | - KOBUNAI TAKASHI ET AL, "Antitumour Activity of S-1 in Combination with Cetuximab on Human Gastric Cancer Cell Lines In Vivo", ANTICANCER RESEARCH, (201111), vol. 31, no. 11, pages 3691 - 3696, XP002678607 [A] 1-14 * the whole document * | - |
| SEARCH | - SAHIN UGUR ET AL, "Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development", CLINICAL CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20081201), vol. 14, no. 23, doi:10.1158/1078-0432.CCR-08-1547, ISSN 1078-0432, pages 7624 - 7634, XP002588324 [A] 1-14 * the whole document * | |
